An Open, Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin Versus Cefuroxime Alone or With Oral Erythromycin for the Treatment of Chinese Patients Who Were Hospitalized for Pneumonia

PHASE3CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

January 31, 2003

Study Completion Date

August 31, 2003

Conditions
Pneumonia
Interventions
DRUG

cefuroxime plus erythromycin

intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days plus erythromycin ethylsuccinate 0.5 g twice daily, which was given for a total duration of 14 days for subjects with suspected pneumonia due to atypical pathogens

DRUG

azithromycin (Zithromax)

intravenous azithromycin 500 mg once daily for 4 +/-1 days, followed by oral azithromycin 500 mg once daily for a total duration of 9 +/-1 days

DRUG

cefuroxime

intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days

Trial Locations (5)

100853

Pfizer Investigational Site, Beijing

200003

Pfizer Investigational Site, Shanghai

200025

Pfizer Investigational Site, Shanghai

200040

Pfizer Investigational Site, Shanghai

200080

Pfizer Investigational Site, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00648726 - An Open, Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin Versus Cefuroxime Alone or With Oral Erythromycin for the Treatment of Chinese Patients Who Were Hospitalized for Pneumonia | Biotech Hunter | Biotech Hunter